Literature DB >> 9578235

Visceral fat as a main determinant of plasminogen activator inhibitor 1 level in women.

B Janand-Delenne1, C Chagnaud, D Raccah, M C Alessi, I Juhan-Vague, P Vague.   

Abstract

OBJECTIVE: To substantiate in a premenopausal population of women, the link between visceral adipose tissue and circulating plasminogen activator inhibitor 1 (PAI-1) levels.
DESIGN: Study of correlations between anthropometric parameters and PAI-1 and evaluation of the changes induced by weight loss.
SUBJECTS: Forty-two healthy pre-menopausal women (aged 18-51 y, with a wide range of body mass index (BMI, 21-48.8 kg/m2). Thirteen women were evaluated after weight loss (6.6+/-3.3 kg). MEASUREMENTS: BMI, waist and hip circumferences. Total, subcutaneous and visceral adipose tissue areas at the L3-L4 level by computed tomography. Insulin, cholesterol, triglyceride, HDL cholesterol, PAI-1 activity, PAI-1 antigen and tissue plasminogen activator (tPA) antigen.
RESULTS: PAI-1 activity, PAI antigen and tPA antigen were positively correlated with visceral adipose tissue, but not with subcutaneous adipose tissue. This correlation was independent of insulin or triglyceride levels. The amount of visceral adipose tissue explained 28% of the PAI-1 activity variance. Weight loss confirmed this link, PAI-1 diminution being correlated only with visceral adipose tissue loss and not with total fat, insulin or triglyceride decrease.
CONCLUSION: This study suggests, like in vitro studies, that visceral fat may be an important contributor to the circulating PAI-1.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9578235     DOI: 10.1038/sj.ijo.0800585

Source DB:  PubMed          Journal:  Int J Obes Relat Metab Disord


  16 in total

1.  Effects of tesamorelin on inflammatory markers in HIV patients with excess abdominal fat: relationship with visceral adipose reduction.

Authors:  Takara L Stanley; Julian Falutz; Jean-Claude Mamputu; Graziella Soulban; Diane Potvin; Steven K Grinspoon
Journal:  AIDS       Date:  2011-06-19       Impact factor: 4.177

2.  Prothrombotic markers in asymptomatic dyslipidemic subjects.

Authors:  David Karasek; Helena Vaverkova; Milan Halenka; Dagmar Jackuliakova; Zdenek Frysak; Ludek Slavik; Dalibor Novotny
Journal:  J Thromb Thrombolysis       Date:  2011-01       Impact factor: 2.300

Review 3.  Treatment of the metabolic syndrome: the impact of lifestyle modification.

Authors:  Allison M Pritchett; John P Foreyt; Douglas L Mann
Journal:  Curr Atheroscler Rep       Date:  2005-03       Impact factor: 5.113

4.  Improved fibrinolysis by an intensive lifestyle intervention in subjects with impaired glucose tolerance. The Finnish Diabetes Prevention Study.

Authors:  H Hämäläinen; T Rönnemaa; A Virtanen; J Lindström; J G Eriksson; T T Valle; P Ilanne-Parikka; S Keinänen-Kiukaanniemi; M Rastas; S Aunola; M Uusitupa; J Tuomilehto
Journal:  Diabetologia       Date:  2005-10-05       Impact factor: 10.122

Review 5.  Plasminogen activator inhibitor-1 (PAI-1): a key factor linking fibrinolysis and age-related subclinical and clinical conditions.

Authors:  Matteo Cesari; Marco Pahor; Raffaele Antonelli Incalzi
Journal:  Cardiovasc Ther       Date:  2010-07-07       Impact factor: 3.023

6.  HDL3, but not HDL2, stimulates plasminogen activator inhibitor-1 release from adipocytes: the role of sphingosine-1-phosphate.

Authors:  Mi-Hye Lee; Samar M Hammad; Andrea J Semler; Louis M Luttrell; Maria F Lopes-Virella; Richard L Klein
Journal:  J Lipid Res       Date:  2010-06-03       Impact factor: 5.922

Review 7.  Fibrinolytic function and coronary risk.

Authors:  I Juhan-Vague; P Morange; M Christine Alessi
Journal:  Curr Cardiol Rep       Date:  1999-07       Impact factor: 2.931

8.  The metabolic phenotype of Prader-Willi syndrome (PWS) in childhood: heightened insulin sensitivity relative to body mass index.

Authors:  Andrea M Haqq; Michael J Muehlbauer; Christopher B Newgard; Steven Grambow; Michael Freemark
Journal:  J Clin Endocrinol Metab       Date:  2010-10-20       Impact factor: 5.958

9.  Adiponectin secretion and response to pioglitazone is depot dependent in cultured human adipose tissue.

Authors:  Susan A Phillips; Theodore P Ciaraldi; Deborah K Oh; Michelle K Savu; Robert R Henry
Journal:  Am J Physiol Endocrinol Metab       Date:  2008-07-29       Impact factor: 4.310

Review 10.  Adipose tissue distribution and risk of metabolic disease: does thiazolidinedione-induced adipose tissue redistribution provide a clue to the answer?

Authors:  X Yang; U Smith
Journal:  Diabetologia       Date:  2007-03-29       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.